Telomir-Zn Study Demonstrates Dose-Dependent Survival, Reduced Hepatic Copper Burden
Telomir Pharmaceuticals published preclinical data showing Telomir-Zn delivered dose-dependent survival improvement and reduced hepatic copper burden, oxidative stress and liver injury biomarkers in an ATP7B-deficient zebrafish model of Wilson’s disease. The study also demonstrated attenuated intracellular calcium dysregulation, improved locomotor function and reduced tissue degeneration across multiple endpoints.
1. Peer-Reviewed Publication
On May 20, Telomir Pharmaceuticals reported that its Telomir-Zn compound yielded significant dose-dependent improvements in a zebrafish Wilson’s disease model, marking the first peer-reviewed publication of this program in the disorder.
2. Preclinical Efficacy Across Endpoints
The study demonstrated reduced hepatic copper accumulation, lowered ROS amplification, attenuated intracellular calcium dysregulation, improved ALT, AST and bilirubin levels, enhanced locomotor function, reduced tissue degeneration and increased survival correlating with higher Telomir-Zn doses.
3. Impact on Development Pipeline
These findings validate Telomir-Zn’s mechanism of intracellular copper modulation and oxidative stress control, bolstering its scientific package as the company advances its lead Triple-Negative Breast Cancer IND-cleared program toward Phase 1/2 clinical trials.